Menu
An expert-led, CME-accredited program aiming to bridge the gaps in the multidisciplinary management of chronic kidney disease (CKD). It looks at improving early diagnosis and staging, and discusses strategies for more collaborative and coordinated care in the different global regions.
This program is suitable for nephrologists, endocrinologists, cardiologists, primary care and any other healthcare professionals who form the multidisciplinary team for CKD and its comorbidities.
Early identification of CKD through screening, followed by accurate diagnosis and staging to inform the best treatment, offers the potential to significantly reduce the morbidity and mortality of this burdensome disease and its complications. Our interactive eLearning will guide you through the steps to reach an early and accurate diagnosis, and when to refer, using evidence-based algorithms and classification systems.
This is now available in multiple languages: French, Spanish, German, Italian, Portuguese, Simplified Chinese and Japanese.
This eLearning activity has been endorsed by KDIGO and PCDE.
Chronic kidney disease (CKD) is increasingly understood to be a global health problem but is often under-recognized by both patients and clinicians. This program aims to highlight the burden and unmet needs within CKD identification and management. It looks at the challenges to effective multidisciplinary management of CKD, including achieving early diagnosis and avoiding progression, and discusses how newer antidiabetic agents can be used to improve patient outcomes.
David Wheeler is Professor of Kidney Medicine at University College London, UK, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients with chronic kidney disease.
Professor Wheeler’s other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. He has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR) Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.
Disclosures
David Wheeler discloses the following interests: Ongoing consultancy arrangement with AstraZeneca. Honoraria from Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Napp, Mundipharma, and MSD.
Shelley Zieroth joined the Section of Cardiology at St Boniface Hospital in Winnipeg in July 2006. She is currently an Associate Professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics. She is also Head of the Medical Heart Failure Program for the Winnipeg Regional Health Authority, Cardiac Sciences Program.
Dr Zieroth attended medical school at the University of Manitoba and went on to train in Internal Medicine and Cardiology at the same centre. She completed her Postdoctoral Clinical Fellowship, specializing in Advanced Heart Failure and Cardiac Transplant, at Toronto General Hospital.
She is involved in several heart failure clinical trials as a PI, is National Lead for EMPULSE, DETERMINE and FINE-ARTS clinical trials and she is on the Steering Committee of PARAGLIDE. Her area of research examines the efficacy of new treatments, including food derived bioactives, in heart failure. She is President of the Canadian Heart Failure Society and on the Canadian Cardiovascular Society Primary Panels for both the Heart Failure and Heart Transplant Guidelines. She is also Co-Chair of Canada’s largest annual heart failure meeting, HF Update. Her current passion is working with national and provincial patient advocacy groups and primary care to operationalize hub and spoke models of heart failure care.
Dr Zieroth is actively engaged in Social Media and promotes #cardiotwitter for its rapid access to clinical trial data, publications and free online access to medical education. It is through this engagement that Dr. Zieroth has become recognized as a global supporter and sponsor of women in medicine and cardiology.
Disclosures
Shelley Zieroth discloses the following interests: Consultancy/Advisory board with Abbott, Akcea, AstraZeneca, Amgen, Alnylam, Boehringer-Ingelhaim, Merck, Novartis, Pfizer, Servier; speaker for AstraZeneca, Boehringer-Ingelhaim, Eli-Lilly, Novartis, Servier; Clinical trials for/research and education grants from Amgen, AstraZeneca, Bayer, Boehringer-Ingelhaim, Eidos, Merck, Novartis, and Servier.
Paola Fioretto is Professor in Medicine at the University of Padova, Italy. She started her research on renal physiology in diabetes and, during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes. Among her contributions to the understanding of diabetic kidney disease are the descriptions of the heterogeneity in the structural lesions underlying renal dysfunction in type 2 diabetes, and of reversal of established diabetic glomerulopathy lesions in patients with type 1 diabetes after pancreas transplantation.
Professor Fioretto’s research interest includes the effects of glucose-lowering therapies on the development and progression of diabetic kidney disease.
She has received several awards, including the Albert Renold award from the EASD (European Association for the Study of Diabetes), a Career Development Award from JDFI, the Morgagni Joung Investigator Award, the Novartis Joung Investigator, the Italian Society of Diabetology Award, and the Golgi Prize from the EASD. She has been Vice President of the EASD (2014-2017), and President of the European Diabetic Nephropathy Study Group of the EASD (2005-2007). She has published over 180 papers and 30 book chapters.
Disclosures
Paola Fioretto discloses the following interests: Fees for advisory board/lectures from AstraZeneca, Boehringer-Ingelhaim, Lilly, Mundipharma, Bayer.
Francesc Xavier Cos is a general practitioner graduated in 1997 and currently working as a GP in Sant Martí Primary Health Centres (Catalonian National Health Service) and Head of innovation in Primary Care Barcelona-city in Primary Care Barcelona, Spain. His main areas of interest are Research and Education in Primary Care with a special emphasis on the Diabetes field.
Dr Cos is a member of the Primary Care University Research Institute Jordi Gol and currently its European representative in Diabetes and Endocrine disorders. At this research institution he is an active member in 2 working groups: Diabetes Prevention and Epidemiological Database analysis. He was also the Spanish national representative of the European General Practice Research Network, WONCA Europe research Group (www.egprn.org) on behalf of the Spanish Primary Care society (www.semfyc.es) from 2009 to 2015. He started his activities on Diabetes at GEDAPS “Primary Care Diabetes Study Group” (www.redgdps.org) in1997, working on Diabetes treatment.
In Spain he has been working in many institutional projects for the Catalonian Health Department, (Type 2 Diabetes treatment Guidelines, SBMG recommendations and the Diabetes Expert Patient Programme). He is regularly invited to participate in national and international meetings to lecture as an expert on Diabetes in Primary Care or to develop and conduct educational activities. He also participates in many advisory boards and expert groups.
Dr Cos is currently working in various research projects in Diabetes prevention (DP Transfers), CATRisc, DE-PLAN, DISCOVER, LadyDiab, VERIFY and OBINDIAB. His unit has recently been involved in many randomized clinical trials (Dapagliflozin, Lixisenatide, Early treatment with MET+Vilda). He is also involved in the academic field as an Associate Professor at the medicine department of the Universitat Autonoma de Barcelona since 2009 and he is currently an associate editor of the Primary Care Diabetes journal. In 2009 he was elected as vice chairman of the Primary Care Diabetes Europe (www.pcdeurope.org) and since February 2016 as Chairman elect. In February 2017 he was appointed as Chairman of PCDE for a term of 4 years
Disclosures
Francesc Xavier Cos discloses the following interests: Consultancy for AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk and Sanofi Diabetes, and Sanofi Pasteur; research Support from AstraZeneca, Novartis, SANOFI, Boehringer Ingelheim; speakers bureau for AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Sanofi Diabetes, Sanofi Pasteur.
Carol Pollock is an academic nephrologist with over 390 publications in basic research and clinical medicine and over 24,380 citations in esteemed medical journals. She is an inaugural Fellow of the Australian Academy of Health and Medical Sciences (2015), was conferred a Vice Chancellor’s Award for Excellence in Research Supervision (2012) and recognised as a ‘Distinguished Professor’ by the University of Sydney (2012).
She was the 2014 recipient of the Ministerial Award for Excellence in Cardiovascular Research. She was Scientific Chairman of the 2013 World Congress of Nephrology, held in Hong Kong. She is Chair of Kidney Health Australia, Chair of the Board of the New South Wales (NSW) Bureau of Health Information and Deputy Chair of the Board of the Australian Organ, Tissue and Transplant Authority. She is a member of the Australian National Health and Medical Research Council. Past health/research leadership roles include inaugural Chair of the NSW Agency for Clinical Innovation and immediate past Chair of the NSW Clinical Excellence Commission, remaining as a director of both organisations until April 2016. She was Chair of the Northern Sydney Local Health District Board since its inception in 2011 until Dec 2016. She was the inaugural Chair then co-Chair of the Research Advisory Committee of the Australian and New Zealand Society of Nephrology from 2016 until 2019. She was Director of Research Northern Sydney/Central Coast 2000–2011. She is on the scientific advisory committee of Australian Biotech Company Pharmaxis Pty Ltd, is a Director of Certa Therapeutics, Chairs the Health Advisory Committee for Linéaire Projects and is a Director of the Photobionics Institute. In November 2018 she was made an Ambassador of Business Events Sydney.
Disclosures
Carol Pollock has received honoraria for scientific presentations and/or advisory board attendance from AstraZeneca, Novartis, Chinook, Eli Lilly, Otsuka and Boehringer Ingelheim.
David Sim is a senior consultant in the department of cardiology and director of the heart failure program at the National Heart Center Singapore. He is clinical associate professor at Duke National University of Singapore Graduate Medical School. His sub-specialty interest is in heart failure, mechanical circulatory support, and heart transplantation. He received a fellowship in heart failure and heart transplant at the Alfred Hospital, Melbourne, Australia. He is a member of the committee for the adult heart transplant program in the National Heart Centre Singapore and paediatric heart transplant program in KK Women’s and Children’s Hospital.
Professor Sim also has an interest in palliative care for advanced heart failure. He is the project director for the advanced care planning program in the National Heart Centre Singapore and honorary visiting consultant at Dover Park Hospice. Professor Sim plays an active role in various research projects and clinical trials and is the National Leader for Singapore for a few key global pharmacological heart failure trials. He is the current director of clinical trials and translational research.
He is currently the President of the Heart Failure Society of Singapore and is active in promoting disease awareness of heart failure in Singapore. In the Asia Pacific region, Professor Sim plays an active role setting up heart failure programs in countries such as Vietnam and Mongolia.
Disclosures
David Sim discloses consultancy, advisory board, and/or speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corpus, Medtronic, Merck, Menarini, Novartis, Otsuka, Pfizer, Roche, Servier, Transmedic, and Vifor Pharma. He also discloses a research grant from AstraZeneca.
Professor Juliana Chan is Professor of Medicine and Therapeutics and Director of the Hong Kong Institute of Diabetes and Obesity at the Chinese University of Hong Kong, Prince of Wales Hospital. She is a physician scientist specialised in diabetes and clinical pharmacology. Since 1995, she has led a multidisciplinary team to establish the Hong Kong Diabetes Register as a research-driven quality improvement program, accompanied by a biobank for multiomic analysis in pursuit of precision medicine.
In 2007, her team designed the web-based Joint Asia Diabetes Evaluation (JADE) Technology to promote data-driven personalised care and collaborative research in Asia. Professor Chan has published 500 original articles and 20 book chapters. She is a committee member of international landmark studies and Hong Kong Government research and healthcare policies related to diabetes and non-communicable diseases. She is a recipient of the American Diabetes Association Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes and leads the Lancet Commission Report on Diabetes.
Disclosures
Juliana Chan discloses consultancy, lecture fees, and/or research support through institutions from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Hua Medicine, Lee Powder, Lilly, Merck, MSD, Novartis, Sanofi, Servier, Viatris and Pfizer. She is CEO (pro-bono) of the Asia Diabetes Foundation and Founding director of GemVCare.
Yook-Chin Chia is Head of the Department of Medical Sciences at Sunway University, Malaysia, and remains an honorary professor at the University of Malaya. She is currently the immediate past-president of the Malaysian Society of Hypertension and is the leader of the Malaysian Society of Hypertension-Sunway University Young Investigators Network and the president of the Malaysian Society for World Action on Salt and Sugar for Health, a non-governmental society to promote reduction of salt and sugar consumption in Malaysia.
Professor Chia is also a hypertension specialist for the European Society of Hypertension, and much of her clinical work and research is on hypertension and its related cardiovascular diseases. She participated in the JADE study on diabetes management and on the Diabetes-CKD study lead by Professor Juliana Chan. Her current research activities are with the HOPE-Asia Network, a group of hypertension specialists from Asia.
She is also a member of the editorial board for several journals and mentors young investigators on hypertension and its related cardiovascular diseases research.
Disclosures
Yook-Chin Chia discloses speaker honorarium from Abbott, Boehringer-Ingelheim, Omron, Medtronic Malaysia, Xepa-Sol Malaysia, Pfizer, Sanofi, Servier, and Novartis. She has received research grants from Pfizer and Omron.
Kevin Fernando is a part-time GP Partner and GP Educational Supervisor at the North Berwick Health Centre, North Berwick, UK. He is also Scottish lead of the Primary Care Diabetes Society. His other roles include RCGP Clinical Advisor for Diabetes & Multimorbidity and Education Director for GPnotebook Education.
Dr Fernando graduated from the University of Edinburgh, Edinburgh, UK in 2000 and holds both MRCGP and MRCP (UK) qualifications and has completed a master’s degree in diabetes, which he passed with distinction.
Dr Fernando has been elected to the Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh, and the Academy of Medical Educators for his work in diabetes and medical education.
Disclosures
Kevin Fernando discloses financial or/and non-financial relationship with AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Lilly, MSD, Novo Nordisk, OmniaMed, Roche, Pfizer, Napp, Mundipharma, Amgen, and Sanofi.
In a short video, our global Program Director, David Wheeler highlights the global burden of CKD and how this program addresses the shortfalls in diagnosis and treatment through an interactive and regionally focused educational program.
David Wheeler chairs a multidisciplinary discussion on the key challenges in the diagnosis and management of CKD in Europe and Canada followed by an audience Q&A.
Carol Pollock chairs a discussion on the key challenges in the diagnosis and management of CKD in the Asia-Pacific region followed by an audience Q&A.
Roberto Pecoits-Filho chairs the discussion on the key challenges in the diagnosis and management of CKD in Latin America followed by an audience Q&A.
A 15-minute activity on CKD screening, diagnosis, and staging to guide you through the steps to reach an early and accurate diagnosis and also when to refer for specialist management.
Learners participating in the program will:
Each phase of the program will be available in the following translated format:
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
The program will be certified with AMA PRA Category 1 Credits™; the amount of credits are shown below. Participants should claim only credits commensurate with the extent of their participation in the activities.
AMA PRA Category 1 Credits™ awarded for each activity:
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Planning Committee
In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Greaton Sellers, Jules Morgan, Rebecca Cox, and Rebecca Hills. Greaton Sellers, Jules Morgan, Rebecca Cox, and Rebecca Hills have no financial relationships to disclose.
All relevant financial relationships have been mitigated.
Instructions on how to claim for your credits will be provided at the end of the webinar.
